Our annual sale has begun! Get your discounted market research reports today!
Bi-Specific MAbs Global Market Report 2021 by The Business Research Company is the most comprehensive report available on the market, being wide-ranging both in terms of chronology and geography. It covers the historic period – 2015-2020, and the forecast period – 2021-2025, with additional forecasts for 2025-2030. The report helps gain a truly global perspective as it covers 60 geographies, focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
TBRC’s market report includes a chapter on the COVID-19 impact on the bi-specific MAbs industry, which gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market and how companies can strategize to bounce back from it. With updated market numbers according to the effects of the coronavirus, the report provides the most accurate expected bi-specific MAbs market growth numbers from 2021-2030.
Request a Sample of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp
The global bi-specific MAbs market is expected to grow from $2.93 billion in 2020 to $3.75 billion in 2021 at a compound annual growth rate (CAGR) of 28%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10 billion in 2025 at a CAGR of 28%.
View more on the report:
The Bi-Specific MAbs Global Market Report 2020-30 by The Business Research Company evaluates bi-specific MAbs market size, growth rate, drivers, bi-specific MAbs industry trends, and major companies.
The bi-specific monoclonal antibodies market segments in the report are:
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others
4) By End Use: Hospitals, Research Institutes, Others
The table of contents in TBRC’s bi-specific MAbs market report includes:
- Executive Summary
- Market Characteristics
- Market Trends And Strategies
- Impact Of COVID-19
- Market Size And Growth
- Segmentation
- Regional And Country Analysis
.
.
.
- Competitive Landscape And Company Profiles
- Key Mergers And Acquisitions
- Future Outlook and Potential Analysis
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
